Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVNS AVANOS MEDICAL	$10.72 +3.7%	$11.95	$9.30 ▼ $25.36	$479.34M	1.12	575,957 shs	814,655 shs
AVR Anteris Technologies Global	$3.61 -5.0%	$3.81	$2.34 ▼ $8.79	$137.04M	N/A	165,476 shs	90,445 shs
EMBC Embecta	$10.36 +5.0%	$10.21	$9.20 ▼ $21.48	$576.83M	1.08	537,121 shs	742,398 shs
RXST RxSight	$7.79 +3.2%	$11.25	$6.32 ▼ $58.23	$306.81M	1.16	1.35 million shs	1.20 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVNS AVANOS MEDICAL	+4.11%	-3.99%	-13.10%	-15.30%	-52.38%
AVR Anteris Technologies Global	-5.00%	+12.46%	+2.85%	-14.25%	+360,999,900.00%
EMBC Embecta	+4.96%	+1.97%	-0.67%	-13.67%	-25.20%
RXST RxSight	+3.18%	+0.13%	-39.09%	-40.67%	-83.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVNS AVANOS MEDICAL	1.6509 of 5 stars	0.0	3.0	0.0	0.0	1.0	1.7	2.5
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	4.772 of 5 stars	3.2	3.0	3.3	0.0	4.0	3.3	3.8
RXST RxSight	3.2856 of 5 stars	4.0	4.0	0.0	0.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVNS AVANOS MEDICAL	0.00	N/A	N/A	N/A
AVR Anteris Technologies Global	3.00	Buy	$16.50	357.06% Upside
EMBC Embecta	2.33	Hold	$19.00	83.40% Upside
RXST RxSight	1.91	Reduce	$12.22	56.90% Upside

Current Analyst Ratings Breakdown

Latest AVR, EMBC, RXST, and AVNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$13.00 ➝ $12.00
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00
7/9/2025	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $9.00
7/9/2025	RXST RxSight	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $10.00
7/9/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $9.00
7/9/2025	RXST RxSight	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/9/2025	RXST RxSight	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$25.00 ➝ $9.00
7/9/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
7/9/2025	RXST RxSight	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/23/2025	EMBC Embecta	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVNS AVANOS MEDICAL	$687.80M	0.72	$12.32 per share	0.87	$16.73 per share	0.64
AVR Anteris Technologies Global	$2.70M	48.21	N/A	N/A	$1.74 per share	2.07
EMBC Embecta	$1.08B	0.56	$3.50 per share	2.96	($12.80) per share	-0.81
RXST RxSight	$148.31M	2.13	N/A	N/A	$6.98 per share	1.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVNS AVANOS MEDICAL	-$392.10M	-$10.07	N/A	6.19	N/A	-66.89%	6.16%	4.57%	N/A
AVR Anteris Technologies Global	-$76.29M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
EMBC Embecta	$78.30M	$0.90	11.51	3.37	0.63	4.89%	-19.67%	12.27%	8/8/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.67	N/A	N/A	N/A	-17.90%	-9.54%	-8.51%	N/A

Latest AVR, EMBC, RXST, and AVNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	AVR Anteris Technologies Global	-$0.5333	N/A	N/A	N/A	$0.58 million	N/A
8/8/2025	Q3 2025	EMBC Embecta	$0.7720	N/A	N/A	N/A	$278.15 million	N/A
8/7/2025	Guidance Update	RXST RxSight	-$0.0363	-$0.29	-$0.2537	-$0.29	$39.78 million	$33.64 million
8/5/2025	Q2 2025	AVNS AVANOS MEDICAL	$0.18	$0.17	-$0.01	-$1.66	$165.50 million	$175.00 million
5/13/2025	Q1 2025	AVR Anteris Technologies Global	N/A	-$0.61	N/A	-$0.61	N/A	N/A
5/9/2025	Q2 2025	EMBC Embecta	$0.66	$0.70	+$0.04	$0.40	$261.77 million	$259.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVNS AVANOS MEDICAL	N/A	N/A	N/A	N/A	N/A
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.60	5.79%	N/A	66.67%	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVNS AVANOS MEDICAL	0.12	2.64	1.56
AVR Anteris Technologies Global	N/A	3.67	3.65
EMBC Embecta	N/A	2.48	1.83
RXST RxSight	N/A	12.68	11.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVNS AVANOS MEDICAL	95.17%
AVR Anteris Technologies Global	N/A
EMBC Embecta	93.83%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
AVNS AVANOS MEDICAL	2.64%
AVR Anteris Technologies Global	N/A
EMBC Embecta	0.42%
RXST RxSight	9.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVNS AVANOS MEDICAL	2,227	46.40 million	45.02 million	Optionable
AVR Anteris Technologies Global	138	36.06 million	N/A	N/A
EMBC Embecta	2,100	58.44 million	58.20 million	Optionable
RXST RxSight	220	40.64 million	36.75 million	Optionable

AVR, EMBC, RXST, and AVNS Headlines

Recent News About These Companies

RxSight (RXST) Q2 Loss Beats Estimates

4 hours ago | aol.comA

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

August 7 at 7:16 PM | zacks.com

Investors in RxSight, Inc. Should Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights – RXST

August 7 at 4:36 PM | globenewswire.com

RxSight, Inc. Reports Second Quarter 2025 Financial Results

August 7 at 4:18 PM | globenewswire.com

RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

August 7 at 2:00 PM | globenewswire.com

Deadline Alert: RxSight, Inc. (RXST) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

August 7 at 1:16 PM | globenewswire.com

RXST SHAREHOLDERS: RxSight, Inc. Stock Drop Triggers Securities Fraud Class Action -- Contact ...

August 7 at 9:22 AM | gurufocus.com

RxSight, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm ...

August 7 at 9:22 AM | gurufocus.com

RxSight, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RXST

August 7 at 8:45 AM | prnewswire.com

RXST SHAREHOLDERS: RxSight, Inc. Stock Drop Triggers Securities Fraud Class Action – Contact BFA Law by September 22 if You Lost Money (NASDAQ:RXST)

August 7 at 8:18 AM | globenewswire.com

Brokerages Set RxSight, Inc. (NASDAQ:RXST) Price Target at $17.50

August 7 at 2:13 AM | americanbankingnews.com

RxSight Expands Board with New Director Appointment

August 6 at 11:15 PM | theglobeandmail.com

Shareholders That Lost Money on RxSight, Inc. (RXST) Should Contact Levi & Korsinsky About Pending Class Action - RXST

August 6 at 11:15 PM | theglobeandmail.com

RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. ...

August 6 at 4:13 PM | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

August 6 at 10:00 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

August 6 at 10:00 AM | prnewswire.com

RxSight Appoints Raymond Cohen to Board of Directors

August 6 at 5:41 AM | ocbj.comO

Levi & Korsinsky Notifies RxSight, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – RXST

August 5 at 4:19 PM | globenewswire.com

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages RxSight, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RXST

August 5 at 3:34 PM | globenewswire.com

RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST

August 5 at 11:40 AM | prnewswire.com

RxSight, Inc. (NASDAQ:RXST) Given Average Rating of "Reduce" by Brokerages

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVR, EMBC, RXST, and AVNS Company Descriptions

AVANOS MEDICAL NYSE:AVNS

$10.72 +0.39 (+3.73%)

Closing price 08/7/2025 03:59 PM Eastern

Extended Trading

$10.74 +0.03 (+0.23%)

As of 08/7/2025 05:55 PM Eastern

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Anteris Technologies Global NASDAQ:AVR

$3.61 -0.19 (-5.00%)

As of 08/7/2025 04:00 PM Eastern

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

Embecta NASDAQ:EMBC

$10.36 +0.49 (+4.96%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$10.58 +0.23 (+2.17%)

As of 08/7/2025 06:54 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

RxSight NASDAQ:RXST

$7.79 +0.24 (+3.18%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$7.60 -0.19 (-2.43%)

As of 04:00 AM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time